Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer
Neil E. Bhola, … , Rebecca S. Cook, Carlos L. Arteaga
Neil E. Bhola, … , Rebecca S. Cook, Carlos L. Arteaga
Published February 8, 2013
Citation Information: J Clin Invest. 2013;123(3):1348-1358. https://doi.org/10.1172/JCI65416.
View: Text | PDF
Research Article Oncology Article has an altmetric score of 42

TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer

  • Text
  • PDF
Abstract

After an initial response to chemotherapy, many patients with triple-negative breast cancer (TNBC) have recurrence of drug-resistant metastatic disease. Studies with TNBC cells suggest that chemotherapy-resistant populations of cancer stem-like cells (CSCs) with self-renewing and tumor-initiating capacities are responsible for these relapses. TGF-β has been shown to increase stem-like properties in human breast cancer cells. We analyzed RNA expression in matched pairs of primary breast cancer biopsies before and after chemotherapy. Biopsies after chemotherapy displayed increased RNA transcripts of genes associated with CSCs and TGF-β signaling. In TNBC cell lines and mouse xenografts, the chemotherapeutic drug paclitaxel increased autocrine TGF-β signaling and IL-8 expression and enriched for CSCs, as indicated by mammosphere formation and CSC markers. The TGF-β type I receptor kinase inhibitor LY2157299, a neutralizing TGF-β type II receptor antibody, and SMAD4 siRNA all blocked paclitaxel-induced IL8 transcription and CSC expansion. Moreover, treatment of TNBC xenografts with LY2157299 prevented reestablishment of tumors after paclitaxel treatment. These data suggest that chemotherapy-induced TGF-β signaling enhances tumor recurrence through IL-8–dependent expansion of CSCs and that TGF-β pathway inhibitors prevent the development of drug-resistant CSCs. These findings support testing a combination of TGF-β inhibitors and anticancer chemotherapy in patients with TNBC.

Authors

Neil E. Bhola, Justin M. Balko, Teresa C. Dugger, María Gabriela Kuba, Violeta Sánchez, Melinda Sanders, Jamie Stanford, Rebecca S. Cook, Carlos L. Arteaga

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2010 2009 Total
Citations: 6 19 23 37 41 41 27 30 30 28 24 18 8 1 1 334
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (334)

Title and authors Publication Year
USP9X integrates TGF-β and hypoxia signalings to promote ovarian cancer chemoresistance via HIF-2α-maintained stemness
Zhenlei Zhang, Xiujie Yu, Liqi Wen, Jia'nan Wang, Zhufeng Li, Yu Zhang, Jiayu Cheng, Ronglin Kan, Wanting Zhang, Yan Shen, Shukai Yuan, Li Zhao
Cell death & disease 2025
Biological activity of a series of in silico designed TGFβRI/TGFβRII receptor complex peptide inhibitors
Jacek Plichta, Michał Karbownik, Piotr Kuna, Michał Panek
Journal of cellular and molecular medicine 2025
Exploring TGF-β Signaling in Cancer Progression: Prospects and Therapeutic Strategies
Sheikh KA, Amjad M, Irfan MT, Anjum S, Majeed T, Riaz MU, Jassim AY, Sharif EA, Ibrahim WN
OncoTargets and Therapy 2025
An update on cancer stem cell survival pathways involved in chemoresistance in triple-negative breast cancer
Jan A, Sofi S, Jan N, Mir MA
Future Oncology 2025
One Month of Brief Weekly Magnetic Field Therapy Enhances the Anticancer Potential of Female Human Sera: Randomized Double-Blind Pilot Study
Iversen JN, Tai YK, Yap JL, Abdul Razar RB, Sukumar VK, Wu KY, Ooi MG, Kukumberg M, Adam S, Rufaihah AJ, Franco-Obregón A
Cells 2025
Inhibition of recurrence and metastasis in triple-negative breast cancer through nanoparticle-mediated silencing of LPCAT1 to remodel ATP energy metabolism.
Li X, Li S, Li H, Wu G, Zhao H, Liu S, Xu X, Saw PE
Science China. Life sciences 2025
Transforming Growth Factor-β/Smad Signaling Inhibits Melanoma Cancer Stem Cell Self-Renewal, Tumor Formation and Metastasis
Boudreault J, Wang N, Ghozlan M, Lebrun JJ
Cancers 2024
Drug resistance mechanisms in cancers: Execution of pro-survival strategies.
Dhanyamraju PK
Journal of Biomedical Research 2024
Advances and Challenges in Targeting TGF-β Isoforms for Therapeutic Intervention of Cancer: A Mechanism-Based Perspective
Danielpour D
Pharmaceuticals 2024
The Expression of Serglycin Is Required for Active Transforming Growth Factor β Receptor I Tumorigenic Signaling in Glioblastoma Cells and Paracrine Activation of Stromal Fibroblasts via CXCR-2.
Manou D, Golfinopoulou MA, Alharbi SND, Alghamdi HA, Alzahrani FM, Theocharis AD
Biomolecules 2024
Targeting SMAD3 improves response to oxaliplatin in esophageal adenocarcinoma models by impeding DNA repair
Ballout F, Lu H, Bhat N, Chen L, Peng D, Chen Z, Chen S, Sun X, Giordano S, Corso S, Zaika A, McDonald O, Livingstone AS, El-Rifai W
Clinical cancer research 2024
Genome-wide in vivo CRISPR screen identifies TGFβ3 as actionable biomarker of palbociclib resistance in triple negative breast cancer
Poulet S, Dai M, Wang N, Yan G, Boudreault J, Daliah G, Guillevin A, Nguyen H, Galal S, Ali S, Lebrun JJ
Molecular Cancer 2024
Identification and Pharmacological Targeting of Treatment-Resistant, Stem-like Breast Cancer Cells for Combination Therapy.
Worley J, Noh H, You D, Turunen MM, Ding H, Paull E, Griffin AT, Grunn A, Zhang M, Guillan K, Bush EC, Brosius SJ, Hibshoosh H, Mundi PS, Sims P, Dalerba P, Dela Cruz FS, Kung AL, Califano A
bioRxiv : the preprint server for biology 2024
Multifactoral Immune Modulation Potentiates Durable Remission in Multiple Models of Aggressive Malignancy
Halpert M, Burns B, Rosario S, Withers H, Trivedi A, Hofferek C, Gephart B, Wang H, Vazquez-Perez J, Amanya S, Hyslop S, Yang J, Kemnade J, Sandulache V, Konduri V, Decker W
The FASEB Journal 2024
The regulation of microRNAs on chemoresistance in triple-negative breast cancer: a recent update
Yan LJ, Y. Lau AT, Xu YM
Epigenomics 2024
Overcoming Cancer Resistance: Strategies and Modalities for Effective Treatment
Koirala M, DiPaola M
Biomedicines 2024
The multifaceted role of the stroma in the healthy prostate and prostate cancer.
Di Carlo E, Sorrentino C
Journal of translational medicine 2024
Integrated machine learning algorithms identify KIF15 as a potential prognostic biomarker and correlated with stemness in triple-negative breast cancer.
Guo Q, Qiu P, Pan K, Liang H, Liu Z, Lin J
Scientific reports 2024
Therapy-induced senescence in breast cancer: an overview
Chembukavu SN, Lindsay AJ
Exploration of Targeted Anti-tumor Therapy 2024
Stabilization of TGF‐β Receptor 1 by a Receptor‐Associated Adaptor Dictates Feedback Activation of the TGF‐β Signaling Pathway to Maintain Liver Cancer Stemness and Drug Resistance
Liu K, Tian F, Chen X, Liu B, Tian S, Hou Y, Wang L, Han M, Peng S, Tan Y, Pan Y, Chu Z, Li J, Che L, Chen D, Wen L, Qin Z, Li X, Xiang J, Bian X, Liu Q, Ye X, Wang T, Wang B
Advanced Science 2024
Understanding the chemistry & pharmacology of antibody-drug conjugates in triple-negative breast cancer with special reference to exatecan derivatives.
Sawant S, Naik GG, Sahu AN, Jagtap VA
Medical oncology (Northwood, London, England) 2024
Hypoxia induced cellular and exosomal RPPH1 promotes breast cancer angiogenesis and metastasis through stabilizing the IGF2BP2/FGFR2 axis.
Ning W, Yang J, Ni R, Yin Q, Zhang M, Zhang F, Yang Y, Zhang Y, Cao M, Jin L, Pan Y
Oncogene 2024
Stemness of Cancer: A Study of Triple-negative Breast Cancer From a Neuroscience Perspective.
Djamgoz MBA
Stem cell reviews and reports 2024
Combination of polymeric micelle formulation of TGFβ receptor inhibitors and paclitaxel produces consistent response across different mouse models of Triple‐negative breast cancer
Vinod N, Hwang D, Fussell SC, Owens TC, Tofade OC, Benefield TS, Copling S, Ramsey JD, Rädler PD, Atkins HM, Livingston EE, Ezzell JA, Sokolsky\u2010Papkov M, Yuan H, Perou CM, Kabanov AV
Bioengineering & Translational Medicine 2024
Stemness regulation in prostate cancer: prostate cancer stem cells and targeted therapy
Liang H, Zhou B, Li P, Zhang X, Zhang S, Zhang Y, Yao S, Qu S, Chen J
Annals of Medicine 2024
Proteins Found in the Triple-Negative Breast Cancer Secretome and Their Therapeutic Potential
McHenry PR, Prosperi JR
International journal of molecular sciences 2023
RUNX1 Is Regulated by Androgen Receptor to Promote Cancer Stem Markers and Chemotherapy Resistance in Triple Negative Breast Cancer
Fernández NB, Sosa SM, Roberts JT, Recouvreux MS, Rocha-Viegas L, Christenson JL, Spoelstra NS, Couto FL, Raimondi AR, Richer JK, Rubinstein N
Cells 2023
Preclinical and Clinical Trials of New Treatment Strategies Targeting Cancer Stem Cells in Subtypes of Breast Cancer
Landeros N, Castillo I, Pérez-Castro R
Cells 2023
Synergistic effects of combined cisplatin and Clinacanthus nutans extract on triple negative breast cancer cells
Abu Bakar NF, Yeo ZL, Hussin F, Madhavan P, Lim V, Jemon K, Prabhakaran P
Journal of Taibah University Medical Sciences 2023
Emerging Intrinsic Therapeutic Targets for Metastatic Breast Cancer
Li J, Goh EL, He J, Li Y, Fan Z, Yu Z, Yuan P, Liu DX
Biology 2023
Molecular pathways and therapeutic targets linked to triple-negative breast cancer (TNBC).
Mustafa M, Abbas K, Alam M, Ahmad W, Moinuddin, Usmani N, Siddiqui SA, Habib S
Molecular and Cellular Biochemistry 2023
CXCL8 and the peritoneal metastasis of ovarian and gastric cancer
Fu X, Wang Q, Du H, Hao H
Frontiers in immunology 2023
Combination of Polymeric Micelle Formulation of TGFβ Receptor Inhibitors and Paclitaxel Produce Consistent Response Across Different Mouse Models of TNBC
Vinod N, Hwang D, Fussell SC, Owens TC, Tofade OC, Copling S, Ramsey JD, Rädler PD, Atkins HM, Livingston EE, Ezzell JA, Sokolsky-Papkov M, Yuan H, Perou CM, Kabanov AV
2023
Deciphering Common Traits of Breast and Ovarian Cancer Stem Cells and Possible Therapeutic Approaches.
Lučić I, Kurtović M, Mlinarić M, Piteša N, Čipak Gašparović A, Sabol M, Milković L
International journal of molecular sciences 2023
Copper chelation suppresses epithelial-mesenchymal transition by inhibition of canonical and non-canonical TGF-β signaling pathways in cancer
Poursani EM, Mercatelli D, Raninga P, Bell JL, Saletta F, Kohane FV, Neumann DP, Zheng Y, Rouaen JR, Jue TR, Michniewicz FT, Schadel P, Kasiou E, Tsoli M, Cirillo G, Waters S, Shai-Hee T, Cazzoli R, Brettle M, Slapetova I, Kasherman M, Whan R, Souza-Fonseca-Guimaraes F, Vahdat L, Ziegler D, Lock JG, Giorgi FM, Khanna K, Vittorio O
Cell & Bioscience 2023
Signaling pathways governing the maintenance of breast cancer stem cells and their therapeutic implications
Ordaz-Ramos A, Tellez-Jimenez O, Vazquez-Santillan K
Frontiers in Cell and Developmental Biology 2023
Identification of transcriptional programs using dense vector representations defined by mutual information with GeneVector.
Ceglia N, Sethna Z, Freeman SS, Uhlitz F, Bojilova V, Rusk N, Burman B, Chow A, Salehi S, Kabeer F, Aparicio S, Greenbaum BD, Shah SP, McPherson A
Nature Communications 2023
Long Noncoding RNAs in Taxane Resistance of Breast Cancer
Chen H, Zhang M, Deng Y
International journal of molecular sciences 2023
Recent advances in targeted strategies for triple-negative breast cancer
Zhu S, Wu Y, Song B, Yi M, Yan Y, Mei Q, Wu K
Journal of Hematology & Oncology 2023
Molecular Biology Mechanisms and Emerging Therapeutics of Triple-Negative Breast Cancer
Zhang Z, Zhang R, Li D
Biologics : targets & therapy 2023
Targeting FOXP3 Tumor-Intrinsic Effects Using Adenoviral Vectors in Experimental Breast Cancer
Nicola Candia AJ, Garcia Fallit M, Peña Agudelo JA, Pérez Küper M, Gonzalez N, Moreno Ayala MA, De Simone E, Giampaoli C, Casares N, Seilicovich A, Lasarte JJ, Zanetti FA, Candolfi M
Viruses 2023
Extracellular Vesicles in Triple–Negative Breast Cancer: Immune Regulation, Biomarkers, and Immunotherapeutic Potential
Das K, Paul S, Ghosh A, Gupta S, Mukherjee T, Shankar P, Sharma A, Keshava S, Chauhan SC, Kashyap VK, Parashar D
Cancers 2023
Molecular targets and therapeutic strategies for triple-negative breast cancer.
Bhat Y, Thrishna MR, Banerjee S
Molecular Biology Reports 2023
Breast cancer stem cells generate immune-suppressive T regulatory cells by secreting TGFβ to evade immune-elimination
Mukherjee S, Chakraborty S, Basak U, Pati S, Dutta A, Dutta S, Roy D, Banerjee S, Ray A, Sa G, Das T
Discover. Oncology 2023
A review of biological targets and therapeutic approaches in the management of triple-negative breast cancer.
Kumar H, Gupta NV, Jain R, Madhunapantula SV, Babu CS, Kesharwani SS, Dey S, Jain V
Journal of Advanced Research 2023
Changes in the immune landscape of TNBC after neoadjuvant chemotherapy: correlation with relapse
Moamin MR, Allen R, Woods SL, Brown JE, Nunns H, Juncker-Jensen A, Lewis CE
Frontiers in immunology 2023
Targeting lncRNA16 by GalNAc-siRNA conjugates facilitates chemotherapeutic sensibilization via the HBB/NDUFAF5/ROS pathway.
Liu Y, Wang Y, Liu B, Liu W, Ma Y, Cao Y, Yan S, Zhang P, Zhou L, Zhan Q, Wu N
Science China Life Sciences 2023
Targeting cancer stem cell plasticity in triple-negative breast cancer
Guo Z, Han S
2023
Mechanistic insights into the interplays between neutrophils and other immune cells in cancer development and progression
Z Mahmud, A Rahman, I Mishu, Y Kabir
Cancer and Metastasis Reviews 2022
Cancer stem-like cells evade CD8 + CD103 + tumor-resident memory T (T RM ) lymphocytes by initiating an epithelial-to-mesenchymal transition program in a human lung tumor model
S Corgnac, I Damei, G Gros, A Caidi, S Terry, S Chouaib, M Deloger, F Mami-Chouaib
Journal for ImmunoTherapy of Cancer 2022
Triple-Negative Breast Cancer: A Brief Review About Epidemiology, Risk Factors, Signaling Pathways, Treatment and Role of Artificial Intelligence
N Almansour
Frontiers in Molecular Biosciences 2022
A Gene Prognostic Index Associated With Epithelial-Mesenchymal Transition Predicting Biochemical Recurrence and Tumor Chemoresistance for Prostate Cancer
D Feng, X Shi, Q Xiong, F Zhang, D Li, L Yang
Frontiers in Oncology 2022
Neoantigens and the tumor microenvironment play important roles in the prognosis of high-grade serous ovarian cancer
H Yang, M Yu, S Zhong, Y You, F Feng
Journal of Ovarian Research 2022
Disruption of the pentraxin 3/CD44 interaction as an efficient therapy for triple‐negative breast cancers
Y Hsiao, J Chi, C Li, L Chen, Y Chen, H Liang, Y Lo, J Hong, C Chuu, L Hung, J Du, W Chang, J Wang
Clinical and Translational Medicine 2022
Inhibition of FOXO1‑mediated autophagy promotes paclitaxel‑induced apoptosis of MDA‑MB‑231 cells
K Xu, W Zhu, A Xu, Z Xiong, D Zou, H Zhao, D Jiao, Y Qing, M Jamal, H Wei, H Zhao
Molecular medicine reports 2022
Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC
P Ferrari, C Scatena, M Ghilli, I Bargagna, G Lorenzini, A Nicolini
International journal of molecular sciences 2022
SYT-SSX1 enhances the invasiveness and maintains stem-like cell properties in synovial sarcoma via induction of TGF-β1/Smad signaling
Y Qi, S Dong, Y He, Z Liu, Y Huang, N Wang, Z Zhang, Z Li, M Shi, X Feng, Q Yao, H Zou, J Hu, L Pang, F Li
BMC Cancer 2022
Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy
R Yang, Y Li, H Wang, T Qin, X Yin, X Ma
2022
Loss of function of BRCA1 promotes EMT in mammary tumors through activation of TGFβR2 signaling pathway
F Bai, C Wang, X Liu, D Hollern, S Liu, C Fan, C Liu, S Ren, J Herschkowitz, W Zhu, X Pei
Cell Death and Disease 2022
The Changing Landscape of Systemic Treatment for Cervical Cancer: Rationale for Inhibition of the TGF-β and PD-L1 Pathways
M Birrer, K Fujiwara, A Oaknin, L Randall, L Ojalvo, C Valencia, I Ray-Coquard
Frontiers in Oncology 2022
At the Intersection of Cardiology and Oncology: TGFβ as a Clinically Translatable Therapy for TNBC Treatment and as a Major Regulator of Post-Chemotherapy Cardiomyopathy
A Sulaiman, J Chambers, S Chilumula, V Vinod, R Kandunuri, S McGarry, S Kim
Cancers 2022
Drug resistance in cancer therapy: the Pandora's Box of cancer stem cells
H Rezayatmand, M Razmkhah, I Razeghian-Jahromi
Stem Cell Research & Therapy 2022
Significance of combined TGF‑β1 and survivin expression on the prognosis of patients with triple‑negative breast cancer
N Liu, D Qi, J Jiang, J Zhang, C Yu
Oncology Letters 2022
CXCR2 Small-Molecule Antagonist Combats Chemoresistance and Enhances Immunotherapy in Triple-Negative Breast Cancer
A Ghallab, R Eissa, H Tayebi
Frontiers in pharmacology 2022
The Effect of Intratumoral Interrelation among FOXP3+ Regulatory T Cells on Treatment Response and Survival in Triple-Negative Breast Cancer
N Goda, C Nakashima, I Nagamine, S Otagaki
Cancers 2022
The paradigm of drug resistance in cancer: an epigenetic perspective
S Adhikari, A Bhattacharya, S Adhikary, V Singh, S Gadad, S Roy, C Das
Bioscience Reports 2022
Functionalized Lineage Tracing Can Enable the Development of Homogenization-Based Therapeutic Strategies in Cancer
Gutierrez C, Vilas CK, Wu CJ, Al\u2019Khafaji AM
Frontiers in immunology 2022
Emergence of Nanotechnology as a Powerful Cavalry against Triple-Negative Breast Cancer (TNBC)
Chaudhuri A, Kumar DN, Dehari D, Singh S, Kumar P, Bolla PK, Kumar D, Agrawal AK
Pharmaceuticals 2022
New classification for advanced breast cancer patients experiencing disease progression during salvage treatment: a single-center retrospective cohort study
Wen J, Ren L, Li W, Li J, Huang L, Yuan Z, Chen Q
Annals of translational medicine 2022
MASTL is enriched in cancerous and pluripotent stem cells and influences OCT1/OCT4 levels
Närvä E, Taskinen ME, Lilla S, Isomursu A, Pietilä M, Weltner J, Isola J, Sihto H, Joensuu H, Zanivan S, Norman J, Ivaska J
iScience 2022
Parathyroid Hormone‐Related Protein Inhibition Blocks Triple‐Negative Breast Cancer Expansion in Bone Through Epithelial to Mesenchymal Transition Reversal
Li J, Camirand A, Zakikhani M, Sellin K, Guo Y, Luan X, Mihalcioiu C, Kremer R
JBMR Plus 2022
Breast Cancer Stem Cells: Signaling Pathways, Cellular Interactions, and Therapeutic Implications
Wang L, Jin Z, Master RP, Maharjan CK, Carelock ME, Reccoppa TB, Kim MC, Kolb R, Zhang W
Cancers 2022
Revisiting Epithelial Carcinogenesis.
Méndez-López LF
International journal of molecular sciences 2022
TGFβ selects for pro‐stemness over pro‐invasive phenotypes during cancer cell epithelial–mesenchymal transition
Tsubakihara Y, Ohata Y, Okita Y, Younis S, Eriksson J, Sellin ME, Ren J, ten Dijke P, Miyazono K, Hikita A, Imamura T, Kato M, Heldin C, Moustakas A
Molecular Oncology 2022
Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model of immunotherapy in triple-negative breast cancer
Wang H, Zhao C, Santa-Maria CA, Emens LA, Popel AS
iScience 2022
Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities
Ribeiro R, Carvalho MJ, Goncalves J, Moreira JN
Frontiers in Molecular Biosciences 2022
Recent advances in therapeutic strategies for triple-negative breast cancer.
Li Y, Zhang H, Merkher Y, Chen L, Liu N, Leonov S, Chen Y
Journal of Hematology & Oncology 2022
Challenges for Triple Negative Breast Cancer Treatment: Defeating Heterogeneity and Cancer Stemness.
Mahmoud R, Ordóñez-Morán P, Allegrucci C
Cancers 2022
Loss of endothelial EMCN drives tumor lung metastasis through the premetastatic niche
Zhang G, Li M, Zhou D, Yang X, Zhang W, Gao R
Journal of Translational Medicine 2022
Selectively Targeting Breast Cancer Stem Cells by 8-Quinolinol and Niclosamide
Cámara-Sánchez P, Díaz-Riascos ZV, García-Aranda N, Gener P, Seras-Franzoso J, Giani-Alonso M, Royo M, Vázquez E, Schwartz S Jr, Abasolo I
International journal of molecular sciences 2022
Machine learning-assisted elucidation of CD81-CD44 interactions in promoting cancer stemness and extracellular vesicle integrity.
Ramos EK, Tsai CF, Jia Y, Cao Y, Manu M, Taftaf R, Hoffmann AD, El-Shennawy L, Gritsenko MA, Adorno-Cruz V, Schuster EJ, Scholten D, Patel D, Liu X, Patel P, Wray B, Zhang Y, Zhang S, Moore RJ, Mathews JV, Schipma MJ, Liu T, Tokars VL, Cristofanilli M, Shi T, Shen Y, Dashzeveg NK, Liu H
eLife 2022
Nanoparticles for Chemoimmunotherapy Against Triple-Negative Breast Cancer
Liu S, Li J, Gu L, Wu K, Xing H
International Journal of Nanomedicine 2022
FBXL2 promotes E47 protein instability to inhibit breast cancer stemness and paclitaxel resistance.
Li F, Niu M, Qin K, Guo R, Yi Y, Xu J, Li L, Xie S, Fu M, Wen N, Liao W, Xiao ZJ
Oncogene 2022
Clonal transcriptomics identifies mechanisms of chemoresistance and empowers rational design of combination therapies
Wild SA, Cannell IG, Nicholls A, Kania K, Bressan D, Hannon GJ, Sawicka K
eLife 2022
KDM6A Depletion in Breast Epithelial Cells Leads to Reduced Sensitivity to Anticancer Agents and Increased TGFβ Activity.
Xiao JF, Kua LF, Ding LW, Sun QY, Myint KN, Chia XR, Venkatachalam N, Loh X, Duex JE, Neang V, Zhou S, Li Y, Yang H, Koeffler HP, Theodorescu D
Molecular cancer research : MCR 2022
Tumor-Induced Inflammatory Cytokines and the Emerging Diagnostic Devices for Cancer Detection and Prognosis
AE Kartikasari, CS Huertas, A Mitchell, M Plebanski
Frontiers in Oncology 2021
Autocrine TGF-β in Cancer: Review of the Literature and Caveats in Experimental Analysis
H Ungefroren
International journal of molecular sciences 2021
The Role of TGF-β in Bone Metastases
T Trivedi, GM Pagnotti, TA Guise, KS Mohammad
Biomolecules 2021
Targeting transforming growth factor-β signaling for enhanced cancer chemotherapy
J Chen, Z Ding, S Li, S Liu, C Xiao, Z Li, B Zhang, X Chen, X Yang
Theranostics 2021
N-cadherin mediates the migration of bone marrow-derived mesenchymal stem cells toward breast tumor cells
S Choi, J Yu, W Kim, KS Park
Theranostics 2021
USP1-WDR48 deubiquitinase complex enhances TGF-β induced epithelial–mesenchymal transition of TNBC cells via stabilizing TAK1
D Han, L Wang, B Chen, W Zhao, Y Liang, Y Li, H Zhang, Y Liu, X Wang, T Chen, C Li, X Song, D Luo, Z Li, Q Yang
Cell cycle (Georgetown, Tex.) 2021
A bioinformatic analysis of the inhibin-betaglycan-endoglin/CD105 network reveals prognostic value in multiple solid tumors
E Listik, B Horst, AS Choi, NY Lee, B Győrffy, K Mythreye, DP Bottaro
PloS one 2021
Triple Negative Breast Cancer: A Mountain Yet to Be Scaled Despite the Triumphs
Q Wu, S Siddharth, D Sharma
Cancers 2021
A Concise Review: The Role of Stem Cells in Cancer Progression and Therapy
H Hayat, H Hayat, BF Dwan, M Gudi, JO Bishop, P Wang
OncoTargets and therapy 2021
The Breast Cancer Stem Cells Traits and Drug Resistance
Q Zheng, M Zhang, F Zhou, L Zhang, X Meng
Frontiers in pharmacology 2021
A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)
LJ Goldstein, M Mansutti, C Levy, JC Chang, S Henry, I Fernandez-Perez, J Prausovà, E Staroslawska, G Viale, B Butler, S McCanna, PA Ruffini, MS Wicha, AF Schott, RH Alvarez, AF Schott, M Abu-Khalaf, N Ibrahim, B Daniel, M Meshad, D Kanamori, A Zelnak, M Graham, J Comer, M Huizing, F Duhoux, V Richard, D Verhoeven, M Smakal, M Krasenska, M Kohoutek, M Zimovjanova, E Kubala, M Campone, JM Ferrero, A Goncalves, L Venat-Bouvet, J Medioni, L Biganzoli, HS Parra, P Pedrazzoli, M Colleoni, M Moroni, D Amadori, P Morandi, S Cinieri, P Tomczak, T Sarosiek, M Wojtukiewicz, A Mruk, B Kukielka-Budny, SA Novoa, EV Alonso, MM Jimenez
Breast Cancer Research and Treatment 2021
Cancer Stem Cell for Tumor Therapy
B Huang, X Yan, Y Li
Cancers 2021
Targeting TGFβ signal transduction for cancer therapy
S Liu, J Ren, P ten Dijke
Signal Transduction and Targeted Therapy 2021
BCL9/BCL9L promotes tumorigenicity through immune-dependent and independent mechanisms in triple negative breast cancer
X Wang, M Feng, T Xiao, B Guo, D Liu, C Liu, J Pei, Q Liu, Y Xiao, R Rosin-Arbesfeld, Y Shi, Y Zhou, M Yang, YX Feng, Y Jiang, Z Shao, K Yu, D Zhu
Oncogene 2021
The AXL-PYK2-PKCα axis as a nexus of stemness circuits in TNBC
L Khera, Y Vinik, F Maina, S Lev
2021
Triple Negative Breast Cancer: A Review of Present and Future Diagnostic Modalities
SA Dass, KL Tan, RS Rajan, NF Mokhtar, ER Adzmi, WF Rahman, TA Din, V Balakrishnan
Medicina 2021
Standard of Care and Promising New Agents for the Treatment of Mesenchymal Triple-Negative Breast Cancer
S Mezi, A Botticelli, G Pomati, B Cerbelli, S Scagnoli, S Amirhassankhani, G dAmati, P Marchetti
Cancers 2021
Co-dependency for MET and FGFR1 in basal triple-negative breast cancers
VY Sung, JF Knight, RM Johnson, YE Stern, SM Saleh, P Savage, A Monast, D Zuo, S Duhamel, M Park
npj Breast Cancer 2021
Senescence-Induced Chemoresistance in Triple Negative Breast Cancer and Evolution-Based Treatment Strategies
A Chakrabarty, S Chakraborty, R Bhattacharya, G Chowdhury
Frontiers in Oncology 2021
Current understanding of epigenetics mechanism as a novel target in reducing cancer stem cells resistance
S Keyvani-Ghamsari, K Khorsandi, A Rasul, MK Zaman
Clinical Epigenetics 2021
Acetylation of KLF5 maintains EMT and tumorigenicity to cause chemoresistant bone metastasis in prostate cancer
B Zhang, Y Li, Q Wu, L Xie, B Barwick, C Fu, X Li, D Wu, S Xia, J Chen, WP Qian, L Yang, AO Osunkoya, L Boise, PM Vertino, Y Zhao, M Li, HR Chen, J Kowalski, O Kucuk, W Zhou, JT Dong
Nature Communications 2021
The Context-Dependent Impact of Integrin-Associated CD151 and Other Tetraspanins on Cancer Development and Progression: A Class of Versatile Mediators of Cellular Function and Signaling, Tumorigenesis and Metastasis
S Erfani, H Hua, Y Pan, B Zhou, X Yang
Cancers 2021
Detection of phenotype‐specific therapeutic vulnerabilities in breast cells using a CRISPR loss‐of‐function screen
A Barkovskaya, CM Goodwin, K Seip, B Hilmarsdottir, S Pettersen, C Stalnecker, O Engebraaten, E Briem, CJ Der, SA Moestue, T Gudjonsson, GM Mælandsmo, L Prasmickaite
Molecular Oncology 2021
Comparison of hormonal receptor expression and HER2 status between circulating tumor cells and breast cancer metastases
SM Sanches, AC Braun, VF Calsavara, PN Barbosa, LT Chinen
Clinics 2021
Aurora-A kinase oncogenic signaling mediates TGF-β-induced triple-negative breast cancer plasticity and chemoresistance
M Jalalirad, TC Haddad, JL Salisbury, D Radisky, M Zhang, M Schroeder, A Tuma, E Leof, JM Carter, AC Degnim, JC Boughey, J Sarkaria, J Yu, L Wang, MC Liu, L Zammataro, L Malatino, E Galanis, JN Ingle, MP Goetz, AB DAssoro
Oncogene 2021
Phenotypic Heterogeneity of Triple-Negative Breast Cancer Mediated by Epithelial–Mesenchymal Plasticity
B Kvokačková, J Remšík, MK Jolly, K Souček
Cancers 2021
SOX4 and SMARCA4 cooperatively regulate PI3k signaling through transcriptional activation of TGFBR2
GA Mehta, SP Angus, CA Khella, K Tong, P Khanna, SA Dixon, MP Verzi, GL Johnson, ML Gatza
npj Breast Cancer 2021
Long non-coding RNA ARHGAP5-AS1 inhibits migration of breast cancer cell via stabilizing SMAD7 protein
CL Wang, JC Li, CX Zhou, CN Ma, DF Wang, LL Wo, M He, Q Yin, JR He, Q Zhao
Breast Cancer Research and Treatment 2021
The miR-124-3p/Neuropilin-1 Axis Contributes to the Proliferation and Metastasis of Triple-Negative Breast Cancer Cells and Co-Activates the TGF-β Pathway
J Zhang, X Zhang, Z Li, Q Wang, Y Shi, X Jiang, X Sun
Frontiers in Oncology 2021
Photo-activated chemo-immunotherapy for metastatic cancer using a synergistic graphene nanosystem
F Zhou, M Wang, T Luo, J Qu, WR Chen
Biomaterials 2021
HDAC6 inhibition enhances the anti-tumor effect of eribulin through tubulin acetylation in triple-negative breast cancer cells
T Oba, M Ono, H Matoba, T Uehara, Y Hasegawa, K Ito
Breast Cancer Research and Treatment 2021
Aldehyde dehydrogenase 1A1 and 1A3 isoforms – mechanism of activation and regulation in cancer
M Poturnajova, Z Kozovska, M Matuskova
Cellular Signalling 2021
A triple-drug nanotherapy to target breast cancer cells, cancer stem cells, and tumor vasculature
S El-Sahli, K Hua, A Sulaiman, J Chambers, L Li, E Farah, S McGarry, D Liu, P Zheng, SH Lee, J Cui, M Ekker, M Côté, T Alain, X Li, VM DCosta, L Wang, S Gadde
Cell Death and Disease 2021
Vasculogenic Mimicry in Breast Cancer: Clinical Relevance and Drivers
G Morales-Guadarrama, R García-Becerra, EA Méndez-Pérez, J García-Quiroz, E Avila, L Díaz
Cells 2021
Predictive biomarkers for 5-fluorouracil and oxaliplatin-based chemotherapy in gastric cancers via profiling of patient-derived xenografts
D Na, J Chae, SY Cho, W Kang, A Lee, S Min, J Kang, MJ Kim, J Choi, W Lee, D Shin, A Min, YJ Kim, KH Lee, TY Kim, YS Suh, SH Kong, HJ Lee, WH Kim, H Park, SA Im, HK Yang, C Lee, JI Kim
Nature Communications 2021
Clinically Translatable Approaches of Inhibiting TGF-β to Target Cancer Stem Cells in TNBC
A Sulaiman, S McGarry, SC Chilumula, R Kandunuri, V Vinod
Biomedicines 2021
Therapeutic Associations Comprising Anti-PD-1/PD-L1 in Breast Cancer: Clinical Challenges and Perspectives
F Ledys, L Kalfeist, L Galland, E Limagne, S Ladoire
Cancers 2021
TGF-β Signaling and Resistance to Cancer Therapy
M Zhang, YY Zhang, Y Chen, J Wang, Q Wang, H Lu
Frontiers in Cell and Developmental Biology 2021
Exploiting Canonical TGFβ Signaling in Cancer Treatment
Q Liu, G Chen, J Moore, I Guix, D Placantonakis, M Barcellos-Hoff
Molecular cancer therapeutics 2021
Entrectinib Induces Apoptosis and Inhibits the Epithelial–Mesenchymal Transition in Gastric Cancer with NTRK Overexpression
S Sohn, H Sul, B Kim, H Kim, D Zang
International journal of molecular sciences 2021
Regulation of cancer stem cells in triple negative breast cancer
N Fultang, M Chakraborty, B Peethambaran
2021
Chemotherapy-induced S100A10 recruits KDM6A to facilitate OCT4-mediated breast cancer stemness
Haiquan Lu, Yangyiran Xie, Linh Tran, Jie Lan, Yongkang Yang, Naveena L. Murugan, Ru Wang, Yueyang J. Wang, Gregg L. Semenza
Journal of Clinical Investigation 2020
HDAC8 cooperates with SMAD3/4 complex to suppress SIRT7 and promote cell survival and migration
X Tang, G Li, F Su, Y Cai, L Shi, Y Meng, Z Liu, J Sun, M Wang, M Qian, Z Wang, X Xu, YX Cheng, WG Zhu, B Liu
Nucleic Acids Research 2020
On-Target Anti-TGF-β Therapies Are Not Succeeding in Clinical Cancer Treatments: What Are Remaining Challenges?
AF Teixeira, P ten Dijke, HJ Zhu
Frontiers in Cell and Developmental Biology 2020
TGFβ biology in cancer progression and immunotherapy
R Derynck, SJ Turley, RJ Akhurst
Nature Reviews Clinical Oncology 2020
Cancer-Associated Fibroblasts: Versatile Players in the Tumor Microenvironment
D Ganguly, R Chandra, J Karalis, M Teke, T Aguilera, R Maddipati, MB Wachsmann, D Ghersi, G Siravegna, HJ Zeh, R Brekken, DT Ting, M Ligorio
Cancers 2020
Cancer stem cell secretome in the tumor microenvironment: a key point for an effective personalized cancer treatment
JL de Andrés, C Griñán-Lisón, G Jiménez, JA Marchal
Journal of Hematology & Oncology 2020
If ineffective levels of transforming growth factors and their receptor account for old age being a risk factor for Alzheimer's disease, then increasing TGFBR2 might be therapeutic
J Fessel
Alzheimer's & Dementia: Translational Research & Clinical Interventions 2020
ADRML: anticancer drug response prediction using manifold learning
FA Moughari, C Eslahchi
Scientific Reports 2020
TGFβ and EGF signaling orchestrates the AP-1- and p63 transcriptional regulation of breast cancer invasiveness
A Sundqvist, E Vasilaki, O Voytyuk, Y Bai, M Morikawa, A Moustakas, K Miyazono, CH Heldin, P ten Dijke, H van Dam
Oncogene 2020
Neutrophil: A New Player in Metastatic Cancers
M Wu, M Ma, Z Tan, H Zheng, X Liu
Frontiers in immunology 2020
A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer
LJ Goldstein, RP Perez, D Yardley, LK Han, JM Reuben, H Gao, S McCanna, B Butler, PA Ruffini, Y Liu, RR Rosato, JC Chang
Breast Cancer Research 2020
Cancer Biology and Prevention in Diabetes
SP Srivastava, JE Goodwin
Cells 2020
Prevention of tumor risk associated with the reprogramming of human pluripotent stem cells
K Wuputra, CC Ku, DC Wu, YC Lin, S Saito, KK Yokoyama
Journal of Experimental & Clinical Cancer Research 2020
CD155 contributes to the mesenchymal phenotype of triple‐negative breast cancer
Q Zheng, J Gao, P Yin, W Wang, B Wang, Y Li, C Zhao
Cancer Science 2020
Resistance to Neoadjuvant Treatment in Breast Cancer: Clinicopathological and Molecular Predictors
MR Chica-Parrado, A Godoy-Ortiz, B Jiménez, N Ribelles, I Barragan, E Alba
Cancers 2020
Progress in systemic therapy for triple-negative breast cancer
H Mo, B Xu
Frontiers of Medicine 2020
Deficiency in Dipeptidyl Peptidase-4 Promotes Chemoresistance Through the CXCL12/CXCR4/mTOR/TGFβ Signaling Pathway in Breast Cancer Cells
S Li, Y Fan, A Kumagai, E Kawakita, M Kitada, K Kanasaki, D Koya
International journal of molecular sciences 2020
Epithelial–Mesenchymal Transition Programs and Cancer Stem Cell Phenotypes: Mediators of Breast Cancer Therapy Resistance
AJ Gooding, WP Schiemann
Molecular cancer research : MCR 2020
Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies
MA Medina, G Oza, A Sharma, LG Arriaga, JM Hernández, VM Rotello, JT Ramirez
International journal of environmental research and public health 2020
The testis protein ZNF165 is a SMAD3 cofactor that coordinates oncogenic TGFβ signaling in triple-negative breast cancer
ZA Gibbs, LC Reza, CC Cheng, JM Westcott, K McGlynn, AW Whitehurst
eLife 2020
Comprehensive Proteomic Characterization Reveals Subclass-Specific Molecular Aberrations within Triple-negative Breast Cancer
M Kosok, A Alli-Shaik, BH Bay, J Gunaratne
iScience 2020
ABL1-dependent OTULIN phosphorylation promotes genotoxic Wnt/β-catenin activation to enhance drug resistance in breast cancers
W Wang, M Li, S Ponnusamy, Y Chi, J Xue, B Fahmy, M Fan, GA Miranda-Carboni, R Narayanan, J Wu, ZH Wu
Nature Communications 2020
Transforming Growth Factor-β: A Multifunctional Regulator of Cancer Immunity
VW Xue, JY Chung, CA Córdoba, AH Cheung, W Kang, EW Lam, KT Leung, KF To, HY Lan, PM Tang
Cancers 2020
SETDB2 promoted breast cancer stem cell maintenance by interaction with and stabilization of ΔNp63α protein
L Ying, X Fei, L Jialun, X Jianpeng, W Jie, M Zhaolin, F Hongjia, F Huan, L Sha, W Qiuju, Y Lin, L Cuicui, P You, Z Weiwei, W Lulu, W Jiemin, L Jing, F Jing
International journal of biological sciences 2020
Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances
H Lind, SR Gameiro, C Jochems, RN Donahue, J Strauss, JL Gulley, C Palena, J Schlom
Journal for ImmunoTherapy of Cancer 2020
Oral encapsulated transforming growth factor β1 reduces endogenous levels: Effect on inflammatory bowel disease
L Hammer, S Furtado, E Mathiowitz, DL Auci
World journal of gastrointestinal pharmacology and therapeutics 2020
Three dimensional engineered models to study hypoxia biology in breast cancer
V Aggarwal, O Miranda, PA Johnston, S Sant
Cancer Letters 2020
Translational control of breast cancer plasticity
M Jewer, L Lee, M Leibovitch, G Zhang, J Liu, SD Findlay, KM Vincent, K Tandoc, D Dieters-Castator, DF Quail, I Dutta, M Coatham, Z Xu, A Puri, BJ Guan, M Hatzoglou, A Brumwell, J Uniacke, C Patsis, A Koromilas, J Schueler, GM Siegers, I Topisirovic, LM Postovit
Nature Communications 2020
Recent Advances in Targeting of Breast Cancer Stem Cells Based on Biological Concepts and Drug Delivery System Modification
Z Aaliyari-Serej, A Ebrahimi, B Barazvan, A Ebrahimi-Kalan, K Hajiasgharzadeh, T Kazemi, B Baradaran
Advanced pharmaceutical bulletin 2020
TGF-β is associated with poor prognosis and promotes osteosarcoma progression via PI3K/Akt pathway activation
K Ma, C Zhang, W Li
Cell cycle (Georgetown, Tex.) 2020
RAC1B Induces SMAD7 via USP26 to Suppress TGFβ1-Dependent Cell Migration in Mesenchymal-Subtype Carcinoma Cells
H Ungefroren, A Kumarasinghe, M Musfeldt, C Fiedler, H Lehnert, JU Marquardt
Cancers 2020
Glucocorticoid receptors are required effectors of TGFβ1-induced p38 MAPK signaling to advanced cancer phenotypes in triple-negative breast cancer
CP Kerkvliet, AR Dwyer, CH Diep, RH Oakley, C Liddle, JA Cidlowski, CA Lange
Breast Cancer Research 2020
Role of BET Inhibitors in Triple Negative Breast Cancers
D Khandekar, V Tiriveedhi
Cancers 2020
Prognostic Values of Transforming Growth Factor-Beta Subtypes in Ovarian Cancer
J Zhou, W Jiang, W Huang, M Ye, X Zhu
BioMed Research International 2020
Limiting Self-Renewal of the Basal Compartment by PKA Activation Induces Differentiation and Alters the Evolution of Mammary Tumors
NB Ognjenovic, M Bagheri, GA Mohamed, K Xu, Y Chen, MA Saleem, MS Brown, SH Nagaraj, KE Muller, SA Gerber, BC Christensen, DR Pattabiraman
Developmental Cell 2020
Galunisertib Drives Treg Fragility and Promotes Dendritic Cell-Mediated Immunity against Experimental Lymphoma
SK Hira, A Rej, A Paladhi, R Singh, J Saha, I Mondal, S Bhattacharyya, PP Manna
iScience 2020
MicroRNA-941 regulates the proliferation of breast cancer cells by altering histone H3 Ser 10 phosphorylation
SK Surapaneni, ZR Bhat, K Tikoo
Scientific Reports 2020
microRNAs and Corresponding Targets Involved in Metastasis of Colorectal Cancer in Preclinical In Vivo Models
UH Weidle, U Brinkmann, S Auslaender
Cancer genomics & proteomics 2020
TGF-β causes Docetaxel resistance in Prostate Cancer via the induction of Bcl-2 by acetylated KLF5 and Protein Stabilization
Y Li, B Zhang, L Xiang, S Xia, O Kucuk, X Deng, LH Boise, JT Dong
Theranostics 2020
Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma
Y Qian, Y Gong, Z Fan, G Luo, Q Huang, S Deng, H Cheng, K Jin, Q Ni, X Yu, C Liu
Journal of Hematology & Oncology 2020
Effects of the Tumor Environment on Ion Channels: Implication for Breast Cancer Progression
Halima Ouadid-Ahidouch, Hamid Morjani, Julie Schnipper, Alban Girault, Ahmed Ahidouch
Reviews of Physiology, Biochemistry and Pharmacology 2020
Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers
BA Hancock, YH Chen, JP Solzak, MN Ahmad, DC Wedge, D Brinza, C Scafe, J Veitch, R Gottimukkala, W Short, RV Atale, M Ivan, SS Badve, BP Schneider, X Lu, KD Miller, M Radovich
Breast Cancer Research 2019
CD44 splice isoform switching determines breast cancer stem cell state
H Zhang, RL Brown, Y Wei, P Zhao, S Liu, X Liu, Y Deng, X Hu, J Zhang, XD Gao, Y Kang, AM Mercurio, HL Goel, C Cheng
Genes & development 2019
Micropeptide CIP 2A‐ BP encoded by LINC 00665 inhibits triple‐negative breast cancer progression
B Guo, S Wu, X Zhu, L Zhang, J Deng, F Li, Y Wang, S Zhang, R Wu, J Lu, Y Zhou
The EMBO Journal 2019
miR-425 suppresses EMT and the development of TNBC (triple-negative breast cancer) by targeting the TGF-β 1/SMAD 3 signaling pathway
Y Liu, J Chen
RSC Advances 2019
Increased Smad3 and reduced Smad2 levels mediate the functional switch of TGF-β from growth suppressor to growth and metastasis promoter through TMEPAI/PMEPA1 in triple negative breast cancer
PK Singha, S Pandeswara, H Geng, R Lan, MA Venkatachalam, A Dobi, S Srivastava, P Saikumar
Genes & cancer 2019
The CXCL8-CXCR1/2 Axis as a Therapeutic Target in Breast Cancer Stem-Like Cells
PA Ruffini
Frontiers in Oncology 2019
The Role of Breast Cancer Stem Cells as a Prognostic Marker and a Target to Improve the Efficacy of Breast Cancer Therapy
MG Scioli, G Storti, F DAmico, P Gentile, G Fabbri, V Cervelli, A Orlandi
Cancers 2019
Drug resistance and combating drug resistance in cancer
X Wang, H Zhang, X Chen
2019
Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment
AC Garrido-Castro, NU Lin, K Polyak
Cancer Discovery 2019
Therapeutic and Mechanistic Perspectives of Protein Complexes in Breast Cancer
MP Waterhouse, R Ugur, WT Khaled
Frontiers in Cell and Developmental Biology 2019
The opposing effects of interferon-beta and oncostatin-M as regulators of cancer stem cell plasticity in triple-negative breast cancer
MR Doherty, JG Parvani, I Tamagno, DJ Junk, BL Bryson, HJ Cheon, GR Stark, MW Jackson
Breast Cancer Research 2019
Emerging Role of SOX Proteins in Breast Cancer Development and Maintenance
GA Mehta, P Khanna, ML Gatza
Journal of Mammary Gland Biology and Neoplasia 2019
Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer—How We Can Rise to the Challenge
Nedeljković, Damjanović
Cells 2019
Breast Cancer Stem Cells with Tumor- versus Metastasis-Initiating Capacities Are Modulated by TGFBR1 Inhibition
F Fico, M Bousquenaud, C Rüegg, A Santamaria-Martínez
Stem Cell Reports 2019
Prognostic value of CD8 + PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer
J Yeong, JC Lim, B Lee, H Li, CC Ong, AA Thike, WH Yeap, Y Yang, AY Lim, TK Tay, J Liu, SC Wong, J Chen, EH Lim, J Iqbal, R Dent, EW Newell, PH Tan
Journal for ImmunoTherapy of Cancer 2019
Redox-Responsive Dual Drug Delivery Nanosystem Suppresses Cancer Repopulation by Abrogating Doxorubicin-Promoted Cancer Stemness, Metastasis, and Drug Resistance
J Liu, B Chang, Q Li, L Xu, X Liu, G Wang, Z Wang, L Wang
Advanced Science 2019
CAFs and TGF-β Signaling Activation by Mast Cells Contribute to Resistance to Gemcitabine/Nabpaclitaxel in Pancreatic Cancer
L Porcelli, R Iacobazzi, RD Fonte, S Serratì, A Intini, A Solimando, O Brunetti, A Calabrese, F Leonetti, A Azzariti, N Silvestris
Cancers 2019
Identification of Breast Cancer Stem Cell Related Genes Using Functional Cellular Assays Combined With Single-Cell RNA Sequencing in MDA-MB-231 Cells
E Jonasson, S Ghannoum, E Persson, J Karlsson, T Kroneis, E Larsson, G Landberg, A Ståhlberg
Frontiers in Genetics 2019
Baseline T cell dysfunction by single cell network profiling in metastatic breast cancer patients
SC Formenti, RE Hawtin, N Dixit, E Evensen, P Lee, JD Goldberg, X Li, C Vanpouille-Box, D Schaue, WH McBride, S Demaria
Journal for ImmunoTherapy of Cancer 2019
Exosomal transfer of p-STAT3 promotes acquired 5-FU resistance in colorectal cancer cells
Q Zhang, RX Liu, KW Chan, J Hu, J Zhang, L Wei, H Tan, X Yang, H Liu
Journal of Experimental & Clinical Cancer Research 2019
Prognostic Significance of CD109 Expression in Patients with Ovarian Epithelial Cancer
SY Kim, KU Choi, C Hwang, HJ Lee, JH Lee, DH Shin, JY Kim, MY Sol, JH Kim, KH Kim, DS Suh, BS Kwon
Journal of Pathology and Translational Medcine 2019
The transcription factor LEF1 promotes tumorigenicity and activates the TGF-β signaling pathway in esophageal squamous cell carcinoma
Y Zhao, J Zhu, B Shi, X Wang, Q Lu, C Li, H Chen
Journal of Experimental & Clinical Cancer Research 2019
BMP-4 enhances epithelial mesenchymal transition and cancer stem cell properties of breast cancer cells via Notch signaling
S Choi, J Yu, A Park, MJ Dubon, J Do, Y Kim, D Nam, J Noh, KS Park
Scientific Reports 2019
TGFβ induces stemness through non-canonical AKT-FOXO3a axis in oral squamous cell carcinoma
K Li, L Yang, J Li, C Guan, S Zhang, X Lao, D Ouyang, G Zheng, S Gao, D Wang, Y Liang, G Liao
EBioMedicine 2019
Targeting the phosphoinositide 3-kinase/AKT pathways by small molecules and natural compounds as a therapeutic approach for breast cancer cells
A Soltani, S Torki, MS Ghahfarokhi, MS Jami, M Ghatrehsamani
Molecular Biology Reports 2019
The GEF‐H1/PKD3 signaling pathway promotes the maintenance of triple‐negative breast cancer stem cells
WS Lieb, C Lungu, R Tamas, H Berreth, P Rathert, P Storz, MA Olayioye, A Hausser
International Journal of Cancer 2019
JNK-Dependent cJun Phosphorylation Mitigates TGFβ- and EGF-Induced Pre-Malignant Breast Cancer Cell Invasion by Suppressing AP-1-Mediated Transcriptional Responses
A Sundqvist, O Voytyuk, M Hamdi, HE Popeijus, CB der Burgt, J Janssen, JW Martens, A Moustakas, CH Heldin, P ten Dijke, H van Dam
Cells 2019
Hypoxic tumor microenvironment activates GLI2 via HIF-1α and TGF-β2 to promote chemoresistance in colorectal cancer
YA Tang, Y Chen, Y Bao, S Mahara, SM Yatim, G Oguz, PL Lee, M Feng, Y Cai, EY Tan, SS Fong, Z Yang, P Lan, X Wu, Q Yu
Proceedings of the National Academy of Sciences 2018
Common Metabolic Pathways Implicated in Resistance to Chemotherapy Point to a Key Mitochondrial Role in Breast Cancer
E Abad, Y García-Mayea, C Mir, D Sebastian, A Zorzano, D Potesil, Z Zdrahal, A Lyakhovich, ME Lleonart
Molecular & cellular proteomics : MCP 2018
TGF-β Sustains Tumor Progression through Biochemical and Mechanical Signal Transduction
R Furler, D Nixon, C Brantner, A Popratiloff, C Uittenbogaart
Cancers 2018
SMAD4 gene mutation renders pancreatic cancer resistance to radiotherapy through promotion of autophagy
F Wang, X Xia, C Yang, J Shen, J Mai, HC Kim, D Kirui, Y Kang, JB Fleming, EJ Koay, S Mitra, M Ferrari, H Shen
Clinical cancer research 2018
A Novel TGFβ Trap Blocks Chemotherapeutics-Induced TGFβ1 Signaling and Enhances Their Anticancer Activity in Gynecologic Cancers
H Zhu, X Gu, L Xia, Y Zhou, H Bouamar, J Yang, X Ding, C Zwieb, J Zhang, AP Hinck, LZ Sun, X Zhu
Clinical cancer research 2018
Inhibition of IRE1 RNase activity modulates the tumor cell secretome and enhances response to chemotherapy
SE Logue, EP McGrath, P Cleary, S Greene, K Mnich, A Almanza, E Chevet, RM Dwyer, A Oommen, P Legembre, F Godey, EC Madden, B Leuzzi, J Obacz, Q Zeng, JB Patterson, R Jäger, AM Gorman, A Samali
Nature Communications 2018
Pharmacological Targeting of Cell Cycle, Apoptotic and Cell Adhesion Signaling Pathways Implicated in Chemoresistance of Cancer Cells
D Alimbetov, S Askarova, B Umbayev, T Davis, D Kipling
International journal of molecular sciences 2018
Cancer stem cells in hepatocellular carcinoma: an overview and promising therapeutic strategies
N Wang, S Wang, MY Li, B Hu, L Liu, S Yang, S Yang, Z Gong, PB Lai, GG Chen
Therapeutic advances in medical oncology 2018
Cell-Based Methods for Determination of Efficacy for Candidate Therapeutics in the Clinical Management of Cancer
J Gordon, M Brown, M Reynolds
Diseases 2018
ERβ-mediated induction of cystatins results in suppression of TGFβ signaling and inhibition of triple-negative breast cancer metastasis
JM Reese, ES Bruinsma, AW Nelson, I Chernukhin, JS Carroll, Y Li, M Subramaniam, VJ Suman, V Negron, DG Monroe, JN Ingle, MP Goetz, JR Hawse
Proceedings of the National Academy of Sciences 2018
The Role of Inflammation and Inflammatory Mediators in the Development, Progression, Metastasis, and Chemoresistance of Epithelial Ovarian Cancer
S Savant, S Sriramkumar, H OHagan
Cancers 2018
Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment
LT Phi, IN Sari, YG Yang, SH Lee, N Jun, KS Kim, YK Lee, HY Kwon
Stem Cells International 2018
Interleukin 8 activity influences the efficacy of adenoviral oncolytic immunotherapy in cancer patients
K Taipale, ST Tähtinen, R Havunen, A Koski, I Liikanen, PP Pakarinen, R Koivisto-Korander, M Kankainen, T Joensuu, A Kanerva, A Hemminki
Oncotarget 2018
Combined drug therapeutic strategies for the effective treatment of Triple Negative Breast Cancer
NK Chalakur-Ramireddy, SB Pakala
Bioscience Reports 2018
Docetaxel facilitates lymphatic-tumor crosstalk to promote lymphangiogenesis and cancer progression
AR Harris, MJ Perez, JM Munson
BMC Cancer 2018
Combination of two anti-tubulin agents, eribulin and paclitaxel, enhances anti-tumor effects on triple-negative breast cancer through mesenchymal-epithelial transition
T Oba, KI Ito
Oncotarget 2018
Precision medicine based on tumorigenic signaling pathways for triple‑negative breast cancer (Review)
N Wu, J Zhang, J Zhao, K Mu, J Zhang, Z Jin, J Yu, J Liu
Oncology Letters 2018
Hydroxytyrosol inhibits cancer stem cells and the metastatic capacity of triple-negative breast cancer cell lines by the simultaneous targeting of epithelial-to-mesenchymal transition, Wnt/β-catenin and TGFβ signaling pathways
M Cruz-Lozano, A González-González, JA Marchal, E Muñoz-Muela, MP Molina, FE Cara, AM Brown, G García-Rivas, C Hernández-Brenes, JA Lorente, P Sanchez-Rovira, JC Chang, S Granados-Principal
European Journal of Nutrition 2018
TNBC Challenge: Oligonucleotide Aptamers for New Imaging and Therapy Modalities
S Camorani, M Fedele, A Zannetti, L Cerchia
Pharmaceuticals (Basel, Switzerland) 2018
Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells
J Tian, FA Raffa, M Dai, A Moamer, B Khadang, IY Hachim, K Bakdounes, S Ali, B Jean-Claude, JJ Lebrun
British Journal of Cancer 2018
Cytokines, breast cancer stem cells (BCSCs) and chemoresistance
W Chen, Y Qin, S Liu
Clinical and Translational Medicine 2018
Tumor Hypoxia As an Enhancer of Inflammation-Mediated Metastasis: Emerging Therapeutic Strategies
JW DiGiacomo, DM Gilkes
Targeted Oncology 2018
Transcriptional downregulation of miR-133b by REST promotes prostate cancer metastasis to bone via activating TGF-β signaling
S Huang, Q Wa, J Pan, X Peng, D Ren, Q Li, Y Dai, Q Yang, Y Huang, X Zhang, W Zhou, D Yuan, J Cao, Y Li, P He, Y Tang
Cell Death and Disease 2018
The role of sentrin-specific protease 2 substrate recognition in TGF-β-induced tumorigenesis
CC Chang, YS Huang, YM Lin, CJ Lin, JC Jeng, SM Liu, TL Ho, RT Chang, CA Changou, CC Ho, HM Shih
Scientific Reports 2018
Genetic Aspects of Keratoconus: A Literature Review Exploring Potential Genetic Contributions and Possible Genetic Relationships with Comorbidities
E Loukovitis, K Sfakianakis, P Syrmakesi, E Tsotridou, M Orfanidou, DR Bakaloudi, M Stoila, A Kozei, S Koronis, Z Zachariadis, P Tranos, N Kozeis, M Balidis, Z Gatzioufas, A Fiska, G Anogeianakis
Ophthalmology and Therapy 2018
212Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models
B Kasten, P Oliver, H Kim, J Fan, S Ferrone, K Zinn, D Buchsbaum
International journal of molecular sciences 2018
Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade
RB Holmgaard, DA Schaer, Y Li, SP Castaneda, MY Murphy, X Xu, I Inigo, J Dobkin, JR Manro, PW Iversen, D Surguladze, GE Hall, RD Novosiadly, KA Benhadji, GD Plowman, M Kalos, KE Driscoll
Journal for ImmunoTherapy of Cancer 2018
New insights from the widening homogeneity perspective to target intratumor heterogeneity
M Tong, Z Deng, X Zhang, B He, M Yang, W Cheng, Q Liu
2018
LY2157299 Monohydrate, a TGF-βR1 Inhibitor, Suppresses Tumor Growth and Ascites Development in Ovarian Cancer
Q Zhang, X Hou, B Evans, J VanBlaricom, S Weroha, W Cliby
Cancers 2018
USP11 Enhances TGFβ-Induced Epithelial–Mesenchymal Plasticity and Human Breast Cancer Metastasis
DA Garcia, C Baek, MV Estrada, T Tysl, EJ Bennett, J Yang, JT Chang
Molecular cancer research : MCR 2018
Efficacy of ALK5 Inhibition in Myelofibrosis
Lanzhu Yue, Matthias Bartenstein, Wanke Zhao, Wanting Ho, Ying Han, Cem Murdun, Adam Mailloux, Ling Zhang, Xuefeng Wang, Anjali Budhakoti, Kith Pradhan, Franck Rapaport, Huaquan Wang, Zonghong Shao, Xiubao Ren, Ulrich Steidl, Ross L. Levine, Joe Zhao, Amit Verma, Pearlie Epling-Burnette
JCI Insight 2017
TGFβ1 Promotes Gemcitabine Resistance through Regulating the LncRNA-LET/NF90/miR-145 Signaling Axis in Bladder Cancer
J Zhuang, L Shen, L Yang, X Huang, Q Lu, Y Cui, X Zheng, X Zhao, D Zhang, R Huang, H Guo, J Yan
Theranostics 2017
Breast Cancers Activate Stromal Fibroblast-Induced Suppression of Progenitors in Adjacent Normal Tissue
S Chatterjee, P Basak, E Buchel, J Safneck, LC Murphy, M Mowat, SK Kung, P Eirew, CJ Eaves, A Raouf
Stem Cell Reports 2017
FAD104, a regulator of adipogenesis, is a novel suppressor of TGF-β–mediated EMT in cervical cancer cells
M Goto, S Osada, M Imagawa, M Nishizuka
Scientific Reports 2017
The crossroads of breast cancer progression: insights into the modulation of major signaling pathways
FJ Velloso, AF Bianco, J Farias, N Torres, P Ferruzo, V Anschau, HC Jesus-Ferreira, T Chang, M Sogayar, L Zerbini, R Correa
OncoTargets and therapy 2017
Adaptive metabolic rewiring to chronic SFK inhibition
E Pinedo-Carpio, D Davidson, VL Marignac, J Panasci, R Aloyz
Oncotarget 2017
Enhancing Adoptive Cell Therapy of Cancer through Targeted Delivery of Small-Molecule Immunomodulators to Internalizing or Noninternalizing Receptors
Y Zheng, L Tang, L Mabardi, S Kumari, DJ Irvine
ACS Nano 2017
Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways
SA Ibrahim, R Gadalla, EA El-Ghonaimy, O Samir, HT Mohamed, H Hassan, B Greve, M El-Shinawi, MM Mohamed, M Götte
Molecular Cancer 2017
Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells
JP Burnett, G Lim, Y Li, RB Shah, R Lim, HJ Paholak, SP McDermott, L Sun, Y Tsume, S Bai, MS Wicha, D Sun, T Zhang
Cancer Letters 2017
Targeting TGF-β Signaling for Therapeutic Gain
RJ Akhurst
Cold Spring Harbor perspectives in biology 2017
Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer
M Asaduzzaman, S Constantinou, H Min, J Gallon, ML Lin, P Singh, S Raguz, S Ali, S Shousha, RC Coombes, EW Lam, Y Hu, E Yagüe
Breast Cancer Research and Treatment 2017
EMT/MET at the Crossroad of Stemness, Regeneration and Oncogenesis: The Ying-Yang Equilibrium Recapitulated in Cell Spheroids
E Forte, I Chimenti, P Rosa, F Angelini, F Pagano, A Calogero, A Giacomello, E Messina
Cancers 2017
Pharmacological and immunological targeting of tumor mesenchymalization
JM David, C Dominguez, C Palena
Pharmacology & Therapeutics 2017
Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2–Negative Metastatic Breast Cancer
AF Schott, LJ Goldstein, M Cristofanilli, PA Ruffini, S McCanna, JM Reuben, RP Perez, G Kato, M Wicha
Clinical cancer research 2017
Androgen Receptor Supports an Anchorage-Independent, Cancer Stem Cell-like Population in Triple-Negative Breast Cancer
VN Barton, JL Christenson, MA Gordon, LI Greene, TJ Rogers, K Butterfield, B Babbs, NS Spoelstra, NC D'Amato, A Elias, JK Richer
Cancer research 2017
MYC Inhibition Depletes Cancer Stem-like Cells in Triple-Negative Breast Cancer
A Yang, S Qin, BA Schulte, SP Ethier, KD Tew, GY Wang
Cancer research 2017
MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation
K Lee, JM Giltnane, JM Balko, LJ Schwarz, AL Guerrero-Zotano, KE Hutchinson, MJ Nixon, MV Estrada, V Sánchez, ME Sanders, T Lee, H Gómez, A Lluch, JA Pérez-Fidalgo, MM Wolf, G Andrejeva, JC Rathmell, SW Fesik, CL Arteaga
Cell Metabolism 2017
Potential therapeutic targets of triple-negative breast cancer based on its intrinsic subtype
F Shao, H Sun, CX Deng
Oncotarget 2017
miR-4775 promotes colorectal cancer invasion and metastasis via the Smad7/TGFβ-mediated epithelial to mesenchymal transition
S Zhao, H Sun, W Jiang, Y Mi, D Zhang, Y Wen, D Cheng, H Tang, S Wu, Y Yu, X Liu, W Cui, M Zhang, X Sun, Z Zhou, Z Peng, D Yan
Molecular Cancer 2017
Cyclooxygenase-2 regulates TGFβ-induced cancer stemness in triple-negative breast cancer
J Tian, MY Hachim, IY Hachim, M Dai, C Lo, FA Raffa, S Ali, JJ Lebrun
Scientific Reports 2017
Oncostatin M promotes cancer cell plasticity through cooperative STAT3-SMAD3 signaling
DJ Junk, BL Bryson, JM Smigiel, N Parameswaran, CA Bartel, MW Jackson
Oncogene 2017
Nanoformulations for Combination or Cascade Anticancer Therapy
L Miao, S Guo, CM Lin, Q Liu, L Huang
Advanced Drug Delivery Reviews 2017
Coactosin-like protein CLP/Cotl1 suppresses breast cancer growth through activation of IL-24/PERP and inhibition of non-canonical TGFβ signaling
L Xia, X Xiao, WL Liu, Y Song, TJ Liu, YJ Li, E Zacksenhaus, XJ Hao, Y Ben-David
Oncogene 2017
Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2 + Breast Cancer
AB Hanker, MV Estrada, G Bianchini, PD Moore, J Zhao, F Cheng, JP Koch, L Gianni, DR Tyson, V Sánchez, BN Rexer, ME Sanders, Z Zhao, TP Stricker, CL Arteaga
Cancer research 2017
Exostosin 1 regulates cancer cell stemness in doxorubicin-resistant breast cancer cells
S Manandhar, C Kim, SH Lee, SH Kang, N Basnet, YM Lee
Oncotarget 2017
Neoadjuvant Trials in ER + Breast Cancer: A Tool for Acceleration of Drug Development and Discovery
AL Guerrero-Zotano, CL Arteaga
Cancer Discovery 2017
Leptin signaling and cancer chemoresistance: Perspectives
PV Candelaria, A Rampoldi, A Harbuzariu, RR Gonzalez-Perez
World journal of clinical oncology 2017
The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus
R Vázquez, ME Riveiro, L Astorgues-Xerri, E Odore, K Rezai, E Erba, N Panini, A Rinaldi, I Kwee, L Beltrame, M Bekradda, E Cvitkovic, F Bertoni, R Frapolli, M D'Incalci
Oncotarget 2017
Myxofibrosarcoma primary cultures: molecular and pharmacological profile
AD Vita, F Recine, L Mercatali, G Miserocchi, C Liverani, C Spadazzi, R Casadei, A Bongiovanni, F Pieri, N Riva, D Amadori, T Ibrahim
Therapeutic advances in medical oncology 2017
The inhibition of cordycepin on cancer stemness in TGF-beta induced chemo-resistant ovarian cancer cell
CW Wang, BH Lee, CJ Tai
Oncotarget 2017
Alk5-Inhibition Increases Delivery of Macromolecular and Protein-Bound Contrast Agents to Tumors
Heike Daldrup-Link, suchismita mohanty, Celina Ansari, Olga Lenkov, Aubie Shaw, ken ito, Su Hyun Hong, Matthias Hofmann, Laura Pisani, Nancy Boudreau, Sanjiv Gambhir, Lisa Coussens
JCI Insight 2016
Abnormal expression of TGF-beta type II receptor isoforms contributes to acute myeloid leukemia
Y Wu, M Su, SX Zhang, Y Cheng, XY Liao, BY Lin, YZ Chen
Oncotarget 2016
Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer
K Takai, A Le, VM Weaver, Z Werb
Oncotarget 2016
Epithelial–mesenchymal transition: a new target in anticancer drug discovery
F Marcucci, G Stassi, RD Maria
Nature Reviews Drug Discovery 2016
Trial Watch—Small molecules targeting the immunological tumor microenvironment for cancer therapy
A Buqué, N Bloy, F Aranda, I Cremer, A Eggermont, WH Fridman, J Fucikova, J Galon, R Spisek, E Tartour, L Zitvogel, G Kroemer, L Galluzzi
OncoImmunology 2016
Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence
JM Balko, LJ Schwarz, N Luo, MV Estrada, JM Giltnane, D Davila-Gonzalez, K Wang, V Sanchez, PT Dean, SE Combs, D Hicks, JA Pinto, MD Landis, FD Doimi, R Yelensky, VA Miller, PJ Stephens, DL Rimm, H Gomez, JC Chang, ME Sanders, RS Cook, CL Arteaga
Science Translational Medicine 2016
TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells
HC Tran, Z Wan, MA Sheard, J Sun, JR Jackson, J Malvar, Y Xu, L Wang, R Sposto, ES Kim, S Asgharzadeh, RC Seeger
Clinical cancer research 2016
Anti-Cancer Stem-like Cell Compounds in Clinical Development – An Overview and Critical Appraisal
F Marcucci, C Rumio, F Lefoulon
Frontiers in Oncology 2016
In vitro models of cancer stem cells and clinical applications
SS Franco, K Szczesna, MS Iliou, M Al-Qahtani, A Mobasheri, J Kobolák, A Dinnyés
BMC Cancer 2016
Cancer Stem Cell Plasticity Drives Therapeutic Resistance
M Doherty, J Smigiel, D Junk, M Jackson
Cancers 2016
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
G Bianchini, JM Balko, IA Mayer, ME Sanders, L Gianni
Nature Reviews Clinical Oncology 2016
A prognostic signature based on three-genes expression in triple-negative breast tumours with residual disease
JA Pinto, J Araujo, NK Cardenas, Z Morante, F Doimi, T Vidaurre, JM Balko, HL Gomez
npj Genomic Medicine 2016
Ubiquitin specific protease 21 upregulation in breast cancer promotes cell tumorigenic capability and is associated with the NOD-like receptor signaling pathway
L Peng, Y Hu, D Chen, R Linghu, Y Wang, X Kou, J Yang, S Jiao
Oncology Letters 2016
Chemotherapy enriches for an invasive triple-negative breast tumor cell subpopulation expressing a precursor form of N-cadherin on the cell surface
ER Nelson, S Li, M Kennedy, S Payne, K Kilibarda, J Groth, M Bowie, E Parilla-Castellar, G Ridder, PK Marcom, M Lyes, BL Peterson, M Cook, SV Pizzo, DP McDonnell, RE Bachelder
Oncotarget 2016
Radiation-enhanced therapeutic targeting of galectin-1 enriched malignant stroma in triple negative breast cancer
M Upreti, A Jyoti, SE Johnson, EP Swindell, D Napier, P Sethi, R Chan, JM Feddock, HL Weiss, TV OHalloran, BM Evers
Oncotarget 2016
Galunisertib (LY2157299), a transforming growth factor-β receptor I kinase inhibitor, attenuates acute pancreatitis in rats
X Liu, M Yu, Y Chen, J Zhang
Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas / Sociedade Brasileira de Biofisica ... [et al.] 2016
Dynamic cohesin‐mediated chromatin architecture controls epithelial–mesenchymal plasticity in cancer
J Yun, SH Song, HP Kim, SW Han, EC Yi, TY Kim
EMBO reports 2016
Expression of transforming growth factor β1 promotes cholangiocarcinoma development and progression
CK Huang, A Aihara, Y Iwagami, T Yu, R Carlson, H Koga, M Kim, J Zou, S Casulli, JR Wands
Cancer Letters 2016
Galunisertib inhibits glioma vasculogenic mimicry formation induced by astrocytes
C Zhang, W Chen, X Zhang, B Huang, A Chen, Y He, J Wang, X Li
Scientific Reports 2016
Effects of Two Common Promoter Polymorphisms of Transforming Growth Factor-β1 on Breast Cancer Risks in Ahvaz, West South of Iran
S Parvizi, G Mohammadzadeh, M Karimi, M Noorbehbahani, A Jafary
Iranian journal of cancer prevention 2016
Transforming growth factor β as regulator of cancer stemness and metastasis
C Bellomo, L Caja, A Moustakas
British Journal of Cancer 2016
Transforming Growth Factor β Mediates Drug Resistance by Regulating the Expression of Pyruvate Dehydrogenase Kinase 4 in Colorectal Cancer
Y Zhang, Y Zhang, L Geng, H Yi, W Huo, G Talmon, YC Kim, SM Wang, J Wang
The Journal of biological chemistry 2016
CDK4 regulates cancer stemness and is a novel therapeutic target for triple-negative breast cancer
M Dai, C Zhang, A Ali, X Hong, J Tian, C Lo, N Fils-Aimé, SA Burgos, S Ali, JJ Lebrun
Scientific Reports 2016
Fucose-containing fraction of Ling-Zhi enhances lipid rafts-dependent ubiquitination of TGFβ receptor degradation and attenuates breast cancer tumorigenesis
SM Tsao, HY Hsu
Scientific Reports 2016
In silico Pathway Activation Network Decomposition Analysis (iPANDA) as a method for biomarker development
IV Ozerov, KV Lezhnina, E Izumchenko, AV Artemov, S Medintsev, Q Vanhaelen, A Aliper, J Vijg, AN Osipov, I Labat, MD West, A Buzdin, CR Cantor, Y Nikolsky, N Borisov, I Irincheeva, E Khokhlovich, D Sidransky, ML Camargo, A Zhavoronkov
Nature Communications 2016
A polyethylenimine-modified carboxyl-poly(styrene/acrylamide) copolymer nanosphere for co-delivering of CpG and TGF-β receptor I inhibitor with remarkable additive tumor regression effect against liver cancer in mice
S Liang, J Hu, Y Xie, Q Zhou, Y Zhu, X Yang
International Journal of Nanomedicine 2016
Hypoxia-inducible factors regulate pluripotency factor expression by ZNF217- and ALKBH5-mediated modulation of RNA methylation in breast cancer cells
C Zhang, WI Zhi, H Lu, D Samanta, I Chen, E Gabrielson, GL Semenza
Oncotarget 2016
Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathway.
Kim S, Lee J, Jeon M, Lee JE, Nam SJ
Oncotarget 2016
Corrigendum: IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel
ZN Wee, SM Yatim, VK Kohlabauer, M Feng, JY Goh, Y Bao, PL Lee, S Zhang, PP Wang, E Lim, WL Tam, Y Cai, HJ Ditzel, DS Hoon, EY Tan, Q Yu
Nature Communications 2015
Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway
M Lahn, S Herbertz, JS Sawyer, AJ Stauber, I Gueorguieva, KE Driscoll, ST Estrem, AL Cleverly, D Desaiah, SC Guba, KA Benhadji, CA Slapak
Drug design, development and therapy 2015
Combination cancer immunotherapy and new immunomodulatory targets
KM Mahoney, PD Rennert, GJ Freeman
Nature Reviews Drug Discovery 2015
Therapeutic targets of triple-negative breast cancer: a review: Therapeutic targets of triple-negative breast cancer
VS Jamdade, N Sethi, NA Mundhe, P Kumar, M Lahkar, N Sinha
British Journal of Pharmacology 2015
Wound Healing and Cancer Stem Cells: Inflammation as a Driver of Treatment Resistance in Breast Cancer
Sims-Mourtada, K Arnold, L Opdenaker, D Flynn
Cancer Growth and Metastasis 2015
Identifying and targeting tumor-initiating cells in the treatment of breast cancer
W Wei, MT Lewis
Endocrine Related Cancer 2015
New Findings on Breast Cancer Stem Cells: A Review
A Bozorgi, M Khazaei, MR Khazaei
Journal of Breast Cancer 2015
Increased Oxidative Stress as a Selective Anticancer Therapy
J Liu, Z Wang
Oxidative medicine and cellular longevity 2015
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
H Lu, D Samanta, L Xiang, H Zhang, H Hu, I Chen, JW Bullen, GL Semenza
Proceedings of the National Academy of Sciences 2015
Common stemness regulators of embryonic and cancer stem cells
Christiana Hadjimichael, Konstantina Chanoumidou, Natalia Papadopoulou, Panagiota Arampatzi, Joseph Papamatheakis, Androniki Kretsovali
World journal of stem cells 2015
IMP3 promotes stem-like properties in triple-negative breast cancer by regulating SLUG
S Samanta, H Sun, HL Goel, B Pursell, C Chang, A Khan, DL Greiner, S Cao, E Lim, LD Shultz, AM Mercurio
Oncogene 2015
Nuclear basic fibroblast growth factor regulates triple-negative breast cancer chemo-resistance
S Li, S Payne, F Wang, P Claus, Z Su, J Groth, J Geradts, G Ridder, R Alvarez, PK Marcom, SV Pizzo, RE Bachelder
Breast Cancer Research 2015
The Fate of Chemoresistance in Triple Negative Breast Cancer (TNBC)
EA OReilly, L Gubbins, S Sharma, R Tully, MH Guang, K Weiner-Gorzel, J McCaffrey, M Harrison, F Furlong, M Kell, A McCann
BBA Clinical 2015
Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population
NE Bhola, VM Jansen, JP Koch, H Li, L Formisano, JA Williams, JR Grandis, CL Arteaga
Cancer research 2015
Cancer stem cells: a potential target for cancer therapy
H Qiu, X Fang, Q Luo, G Ouyang
Cellular and Molecular Life Sciences 2015
The Anticancer Effect of (1S,2S,3E,7E,11E)-3,7,11, 15-Cembratetraen-17,2-olide(LS-1) through the Activation of TGF-β Signaling in SNU-C5/5-FU, Fluorouracil-Resistant Human Colon Cancer Cells
EJ Kim, JI Kang, JW Kwak, CH Jeon, NH Tung, YH Kim, CH Choi, JW Hyun, YS Koh, ES Yoo, HK Kang
Marine drugs 2015
Regulation of stem cells-related signaling pathways in response to doxorubicin treatment in Hs578T triple-negative breast cancer cells
O Tudoran, O Soritau, L Balacescu, S Visan, O Barbos, R Cojocneanu-Petric, O Balacescu, I Berindan-Neagoe
Molecular and Cellular Biochemistry 2015
Heat shock factor 1 induces cancer stem cell phenotype in breast cancer cell lines
B Wang, CW Lee, A Witt, A Thakkar, TA Ince
Breast Cancer Research and Treatment 2015
Blockage of TGFβ-SMAD2 by demethylation-activated miR-148a is involved in caffeic acid-induced inhibition of cancer stem cell-like properties in vitro and in vivo
Y Li, F Jiang, L Chen, Y Yang, S Cao, Y Ye, X Wang, J Mu, Z Li, L Li
FEBS Open Bio 2015
Therapeutic Implications of Cellular Heterogeneity and Plasticity in Breast Cancer
MD Brooks, ML Burness, MS Wicha
Cell Stem Cell 2015
Aldehyde dehydrogenase as a marker and functional mediator of metastasis in solid tumors
M Rodriguez-Torres, AL Allan
Clinical & Experimental Metastasis 2015
MEK-dependent IL-8 induction regulates the invasiveness of triple-negative breast cancer cells
S Kim, J Lee, M Jeon, JE Lee, SJ Nam
Tumor Biology 2015
Combinatorial TGF-β attenuation with paclitaxel inhibits the epithelial-to-mesenchymal transition and breast cancer stem-like cells
Park SY, Kim MJ, Park SA, Kim JS, Min KN, Kim DK, Lim W, Nam JS, Sheen YY
Oncotarget 2015
Targeting CXCR1 on breast cancer stem cells: signaling pathways and clinical application modelling
Brandolini L, Cristiano L, Fidoamore A, De Pizzol M, Di Giacomo E, Florio TM, Confalone G, Galante A, Cinque B, Benedetti E, Ruffini PA, Cifone MG, Giordano A, Alecci M, Allegretti M, Cimini A
Oncotarget 2015
Melanoma-initiating cells exploit M2 macrophage TGFβ and arginase pathway for survival and proliferation
Muly Tham, Kar Wai Tan, Jo Keeble, Xiaojie Wang, Sandra Hubert, Luke Barron, Nguan Soon Tan, Masashi Kato, Armelle Prevost-Blondel, Veronique Angeli, Jean-Pierre Abastado
Oncotarget 2014
Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells
D Samanta, DM Gilkes, P Chaturvedi, L Xiang, GL Semenza
Proceedings of the National Academy of Sciences 2014
Two Faces of TGF-Beta1 in Breast Cancer
JM Zarzynska
Mediators of Inflammation 2014
Novel clinical therapeutics targeting the epithelial to mesenchymal transition
AN Kothari, Z Mi, M Zapf, PC Kuo
Clinical and Translational Medicine 2014
Validation of the effects of TGF-β1 on tumor recurrence and prognosis through tumor retrieval and cell mechanical properties
TH Wu, YW Chou, PH Chiu, MJ Tang, CW Hu, ML Yeh
Cancer Cell International 2014
SHOX2 Is a Direct miR-375 Target and a Novel Epithelial-to-Mesenchymal Transition Inducer in Breast Cancer Cells
S Hong, H Noh, Y Teng, J Shao, H Rehmani, HF Ding, Z Dong, SB Su, H Shi, J Kim, S Huang
Neoplasia (New York, N.Y.) 2014
Concise Review: Breast Cancer Stem Cells: Regulatory Networks, Stem Cell Niches, and Disease Relevance
W Guo
Stem Cells Translational Medicine 2014
The miR-424(322)/503 cluster orchestrates remodeling of the epithelium in the involuting mammary gland
D Llobet-Navas, R Rodriguez-Barrueco, V Castro, AP Ugalde, P Sumazin, D Jacob-Sendler, B Demircan, M Castillo-Martin, P Putcha, N Marshall, P Villagrasa, J Chan, F Sanchez-Garcia, D Pe'er, R Rabadan, A Iavarone, C Cordon-Cardo, A Califano, C Lopez-Otin, E Ezhkova, JM Silva
Genes & development 2014
Tackling the cancer stem cells — what challenges do they pose?
DR Pattabiraman, RA Weinberg
Nature Reviews Drug Discovery 2014
Par6 is an essential mediator of apoptotic response to transforming growth factor beta in NMuMG immortalized mammary cells
G Avery-Cooper, M Doerr, RW Gilbert, M Youssef, A Richard, P Huether, AM Viloria-Petit
Cancer Cell International 2014
Combined targeting of TGF-β1 and integrin β3 impairs lymph node metastasis in a mouse model of non-small-cell lung cancer
E Salvo, S Garasa, J Dotor, X Morales, R Peláez, P Altevogt, A Rouzaut
Molecular Cancer 2014
Aurora-A Mitotic Kinase Induces Endocrine Resistance through Down-Regulation of ERα Expression in Initially ERα+ Breast Cancer Cells
M Opyrchal, JL Salisbury, S Zhang, J McCubrey, J Hawse, MP Goetz, GA Lomberk, T Haddad, A Degnim, C Lange, JN Ingle, E Galanis, AB D'Assoro
PloS one 2014
The Repressive Effect of miR-148a on TGF beta-SMADs Signal Pathway Is Involved in the Glabridin-Induced Inhibition of the Cancer Stem Cells-Like Properties in Hepatocellular Carcinoma Cells
F Jiang, J Mu, X Wang, X Ye, L Si, S Ning, Z Li, Y Li
PloS one 2014
Metformin Inhibits the IL-6-Induced Epithelial-Mesenchymal Transition and Lung Adenocarcinoma Growth and Metastasis
Z Zhao, X Cheng, Y Wang, R Han, L Li, T Xiang, L He, H Long, B Zhu, Y He
PloS one 2014
NF-κB Affects Proliferation and Invasiveness of Breast Cancer Cells by Regulating CD44 Expression
SM Smith, YL Lyu, L Cai
PloS one 2014
TGF  Induces "BRCAness" and Sensitivity to PARP Inhibition in Breast Cancer by Regulating DNA-Repair Genes
L Liu, W Zhou, CT Cheng, X Ren, G Somlo, MY Fong, AR Chin, H Li, Y Yu, Y Xu, ST O'Connor, TR O'Connor, DK Ann, JM Stark, SE Wang
Molecular cancer research : MCR 2014
7-difluoromethoxyl-5,4′-di-n-octyl genistein inhibits ovarian cancer stem cell characteristics through the downregulation of FOXM1
YX Ning, QX Li, KQ Ren, MF Quan, JG Cao
Oncology Letters 2014
Binding of a Smad4/Ets-1 complex to a novel intragenic regulatory element in exon12 of FPGS underlies decreased gene expression and antifolate resistance in leukemia
Raz S, Stark M, Assaraf YG
Oncotarget 2014
TGF-β
D Brunen, SM Willems, U Kellner, R Midgley, I Simon, R Bernards
Cell cycle (Georgetown, Tex.) 2013
Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets
JM Balko, JM Giltnane, K Wang, LJ Schwarz, CD Young, RS Cook, P Owens, ME Sanders, MG Kuba, V Sánchez, R Kurupi, PD Moore, JA Pinto, FD Doimi, H Gómez, D Horiuchi, A Goga, BD Lehmann, JA Bauer, JA Pietenpol, JS Ross, GA Palmer, R Yelensky, M Cronin, VA Miller, PJ Stephens, CL Arteaga
Cancer Discovery 2013
Identification of FDA-approved drugs targeting breast cancer stem cells along with biomarkers of sensitivity
P Bhat-Nakshatri, CP Goswami, S Badve, GW Sledge, H Nakshatri
Scientific Reports 2013
Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer
L Xiang, DM Gilkes, P Chaturvedi, W Luo, H Hu, N Takano, H Liang, GL Semenza
Journal of Molecular Medicine 2013
Epigenetic coordination of signaling pathways during the epithelial-mesenchymal transition
M Cieślik, SA Hoang, N Baranova, S Chodaparambil, M Kumar, DF Allison, X Xu, JJ Wamsley, L Gray, DR Jones, MW Mayo, S Bekiranov
Epigenetics & chromatin 2013
Can nanomedicines kill cancer stem cells?
Y Zhao, DY Alakhova, AV Kabanov
Advanced Drug Delivery Reviews 2013
Targeted cancer therapy – Are the days of systemic chemotherapy numbered?
WD Joo, I Visintin, G Mor
Maturitas 2013
Perspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas
Neuzillet C, de Gramont A, Tijeras-Raballand A, de Mestier L, Cros J, Faivre S, Raymond E
Oncotarget 2013
Cardamonin reduces chemotherapy-enriched breast cancer stem-like cells in vitro and in vivo
D Jia, Y Tan, H Liu, S Ooi, L Li, K Wright, S Bennett, CL Addison, L Wang
Oncotarget 2010
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2009

← Previous 1 2 … 11 12 13 14 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Picked up by 3 news outlets
Blogged by 1
Posted by 7 X users
Referenced in 10 patents
On 1 Facebook pages
Referenced in 2 Wikipedia pages
423 readers on Mendeley
1 readers on CiteULike
See more details